Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 14, 2009, the Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) elected Mark R. Baker President of the Company and a member of its Board of Directors, increasing the number of directors of the Company to nine. Mr. Baker, formerly the Company's Executive Vice President - Corporate, General Counsel and Secretary, will retain the latter titles and continue to report to Paul J. Maddon, M.D., Ph.D., the Company's Founder, Chief Executive Officer and Chief Science Officer. Mr. Baker will serve as a director, subject to his earlier resignation or removal, until the Company's 2010 annual meeting of stockholders and the election and qualification of his successor. He will not receive any additional compensation for service as a director. Additional information concerning Mr. Baker contained in the Company's Proxy Statement for its Annual Meeting of Stockholders held on June 8, 2009 is incorporated herein by reference thereto.

The Company's press release announcing Mr. Baker's election as President and a director is attached as Exhibit 99.1, and the information contained therein is incorporated by reference into this Item 5.02 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated September 16, 2009.

---